Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20687548 | 0.80 | GRM4 (0.33) | NFE2L2DYRK1AAPLNRCYP3A4CYP2D6 | |
| SCHEMBL23620231 | 0.78 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL14853043 | 0.78 | CCR1 (0.39) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL21376391 | 0.78 | ALDH1A1 (0.37) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL27102704 | 0.77 | TLR9 (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL26942083 | 0.75 | CCNB2 (0.34) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL911419 | 0.75 | CCR4 (0.43) | NFE2L2CCR4MAPK1L3MBTL1DYRK1A | |
| SCHEMBL439658 | 0.74 | NFE2L2 (0.36) | NFE2L2CCR4MAPK1L3MBTL1DYRK1A | |
| SCHEMBL13036639 | 0.74 | CCNB2 (0.33) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL21848988 | 0.73 | CD274 (0.36) | NFE2L2CCR4MAPK1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | CCNB2 2018/4885CDK1 440/4885CCNB1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.